Cargando…

Recomendaciones sobre el manejo de pacientes adultos con enfermedades reumáticas en el contexto de la infección por SARS-CoV-2/COVID-19. Asociación Colombiana de Reumatología

OBJECTIVE: To produce recommendations for patients with rheumatological diseases receiving immunomodulatory and immunosuppressive therapies (conventional drugs, biologicals, and small molecules) during the COVID-19 pandemic. MATERIALS AND METHODS: The recommendations were determined using the Delphi...

Descripción completa

Detalles Bibliográficos
Autores principales: Saldarriaga Rivera, Lina María, Fernández Ávila, Daniel, Bautista Molano, Wilson, Jaramillo Arroyave, Daniel, Bautista Ramírez, Alain Jasaf, Díaz Maldonado, Adriana, Hernán Izquierdo, Jorge, Jáuregui, Edwin, Latorre Muñoz, María Constanza, Restrepo, Juan Pablo, Segura Charry, Juan Sebastián
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Asociación Colombiana de Reumatología. Published by Elsevier España, S.L.U. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7290203/
http://dx.doi.org/10.1016/j.rcreu.2020.05.007
Descripción
Sumario:OBJECTIVE: To produce recommendations for patients with rheumatological diseases receiving immunomodulatory and immunosuppressive therapies (conventional drugs, biologicals, and small molecules) during the COVID-19 pandemic. MATERIALS AND METHODS: The recommendations were determined using the Delphi method as an agreement tool. A panel of experts was formed, with academic backgrounds and research experience in rheumatology. A literature search was conducted and 42 questions were generated. The level of agreement was made with 80% of approval by the participants. RESULTS: A group of eleven rheumatologists from 7 cities in the country participated. The response rate was 100% for the three consultation rounds. In the first round, agreement was reached on 35 questions, on 37 in the second round, and on 42 questions in the third round. CONCLUSION: The recommendation for the majority of the pharmacological treatments used in rheumatology is to continue with immunomodulatory or immunosuppressive therapies in patients who do not have the infection, and to suspend it in patients with a diagnosis of SARS-CoV-2/COVID-19.